Aclarion (ACON) Corporate presentation summary

Product and market opportunity

• Nociscan uses magnetic resonance spectroscopy and proprietary processing to measure pain and structural-integrity biomarkers for each disc, helping identify painful discs.

• The presentation estimates 266M people globally have chronic low back pain and sizes the annual opportunity at $32B globally, based on a $1,450 list price.

• Nociscan is presented as a non-invasive alternative to provocative discography; it can be added to a lumbar MRI and has a $1,450 list price versus $2,000–$5,000 for discography.

Clinical evidence and trial

• A published study reported improvement in 97% of patients when all Nociscan-positive discs were treated, versus 54% when a positive disc was not treated; improvement persisted at two-year follow-up.

• CLARITY is a randomized, controlled, multisite trial targeting 300 patients, with a 12-month primary endpoint; 11 sites were active and the first patient enrolled in Q2 2025.

• CLARITY is intended to compare surgical outcomes when surgeons can access Nociscan data versus when they cannot; the trial is fully funded at an estimated total cost of ~$4.6M.

• Evidence plan cites nine peer-reviewed publications, 250+ patients studied and seven ongoing clinical trials.

Commercial progress and reimbursement

• Nociscan volume grew 85% YoY in Q3 2026; total scan volume grew 117% for the nine months ended September 30, 2026.

• Three of the UK’s top four private medical insurers cover Nociscan, representing 5.2M people; private medical insurance and patient payment account for 72% of UK private hospital revenue.

• U.S. commercial efforts include expanding physician referrals and support; CPT Category III codes cover scan acquisition and algorithmic biomarker post-processing.